BioStock: Aptahem's CEO on signing of non binding Term Sheet
Aptahem announced yesterday that the company has entered into a non binding Term Sheet (NBTS) with a European pharmaceutical company. The NBTS relates to license terms for the exclusive development, manufacturing and distribution of Apta-1 for the treatment of sepsis in Europe. BioStock reached out to CEO Mikael Lindstam to learn more.
Read the full interview with Mikael Lindstam at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se